@Jjs24Jjs $APTO have 2 markets the B-cell like CLL/SLL, FL &amp; more. And the #AML FLT3/ITD if CG-806 succeed in the coming Ph1 study to show what they has in the extensive pre-clinical studies.

To make it easier for you, $MRK paid $2.7B for $ARQL for BTK only, so $APTO have BTK &amp; FLT3!